1 Parkinson B, Sermet C, Clement F, Crausaz S, Godman B, Garner S et al. Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review. PHARMACOECONOMICS. 2015;33(9):905-24. doi:10.1007/s40273-015-0293-8.
2 Smith C. Retail Prescription Drug Spending In The National Health Accounts. HEALTH AFFAIR. 2004;23(1):160-7. doi:10.1377/hlthaff.23.1.160.
3 The IQVIA Institute. Global Medicine Spending and Usage Trends Outlook to 2024. 2020.https://www.iqvia.com/insights/the-iqvia-institute/reports/global-medicine-spending-and-usage-trends.
4 The Central People's Government of the People's Republic of China. 2019 Statistical Bulletin of China's Health Development. 2020.http://www.gov.cn/guoqing/2021-04/09/content_5598657.htm.
5 National Health Development Research Center of the National Health Commission. 2018 China Total Health Expenditure Research Report. Beijing: Institute of health and economy press; 2018.
6 Mao Z, Yang Y, Chen L. Reform of Drug Supply and Guarantee System in China: Policy Measures and Effects. In: Wang C, Liang W, ''editors'. Development Report on Health Reform in China (2020): Beijing: Social Sciences Academic Press; 2020. p. 96-123.
7 Dylst P, Vulto A, Simoens S. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? HEALTH POLICY. 2011;101(2):146-52. doi:10.1016/j.healthpol.2011.03.004.
8 Seidman G, Atun R. Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries. BMJ Glob Health. 2017;2(2):e243. doi:10.1136/bmjgh-2016-000243.
9 General Office of the State Council of the People's Republic of China. Pilot Program for National Centralized Drug Procurement and Use. 2019.http://www.gov.cn/zhengce/content/2019-01/17/content_5358604.htm.
10 Joint Procurement Office. 4+7 City Drug Centralized Procurement Documents (No. GY-YD2018-1). 2018.http://www.smpaa.cn/gjsdcg/2018/11/15/8511.shtml.
11 Joint Procurement Office. The results of 4+7 city drug centralized procurement. 2018.http://www.smpaa.cn/gjsdcg/2018/12/07/8531.shtml.
12 国家医保局, National Healthcare Security Administration. Letter from the National Health Security Administration on the Reply to Proposal No. 4733 (Economic Development No. 260) of the Third Meeting of the Thirteenth National Committee of the Chinese People's Political Consultative Conference. 2020.http://www.nhsa.gov.cn/art/2020/12/23/art_26_4167.html.
13 Zhang M. Trends in the development of centralized drug procurement in China. The 5th Wuhan University Luojia Cherry Blossom Forum2021.
14 Huang X, Li C, Pan Z. Analysis on the Effect of Drug Centralized Procurement Organized by the State in A Tertiary-grade Class A Hospital. Pharmacy Today. 2020;30(12):854-7. doi:10.12048/j.issn.1674-229X.2020.12.015.
15 Zou G, Zhao J, Mei Q, Ye H, Zhou H, Zhu X et al. Analysis of Application of Original Drugs and Generic Drugs after the Implementation of "4+7 Cities" Group Procurement of Drugs in Guangdong Second Provincial Central Hospital. Evaluation and analysis of drug-use in hospitals of China. 2020;20(07):854-8. doi:10.14009/j.issn.1672-2124.2020.07.022.
16 Chen H, Liu Y, Yu X, Zhang D, Zhou H, Feng W et al. Data Analysis on Pilot Reform of Drug Centralized Procurement and Use—Taking Beijing Chaoyang Hospital as an Example. China Health Insurance. 2019(08):51-3. doi:10.19546/j.issn.1674-3830.2019.8.012.
17 Wang Q, Liu D, Yuan W, Huang J, Wang Q, Zhang R. An Annual Effect Analysis on the First Batch of Pilot Project of National-Organized Centralized Drug Procurement and Application in A Certain Grade Ⅲ Level A General Hospital in Chongqing. Evaluation and analysis of drug-use in hospitals of China. 2021;21(02):237-9. doi:10.14009/j.issn.1672-2124.2021.02.026.
18 Xu X, Tang J, Zhang X, Zhang T. Analysis on the Influencing Factors of Patients Using National Centralized Purchasing Drugs—Taking a Tertiary Hospital in Beijing as an Example. China Health Insurance. 2020(07):61-4. doi:10.19546/j.issn.1674-3830.2020.7.013.
19 Chen J, Tian Y, Shi LW. The Impact of Generic Drug Entry on Market Shares and Prices of Brand-Name Drugs– Evidence from Chinese Pharmaceutical Market. VALUE HEALTH. 2018;21:S9. doi:https://doi.org/10.1016/j.jval.2018.07.065.
20 Mu A. Preliminary Analysis on the Pilot Project of Drug Centralized Procurement and Use in Chongqing. China Health Insurance. 2019(08):24-7. doi:10.19546/j.issn.1674-3830.2019.8.006.
21 Meng L. Analysis on the Pilot Operation of Drug Centralized Procurement and Use in Shenyang. China Health Insurance. 2019(08):28-31. doi:10.19546/j.issn.1674-3830.2019.8.007.
22 Shenzhen Healthcare Security Bureau. Pilot Analysis on Drug Centralized Procurement and Use Organized by the State in Shenzhen. China Health Insurance. 2019(08):32-7. doi:10.19546/j.issn.1674-3830.2019.8.008.
23 Cao G, Li P, Wang Y, Liu Y, Guo Z. Analysis of the first quantity purchase of antihypertensive drugs in our hospital. Chinese Community Doctors. 2021;37(03):14-6. doi:10.3969/j.issn.1007-614x.2021.03.006.
24 Li Q, Liu Y, Zhuo S. A Hospital's "4+7" Drug Quantity Procurement Model. China Health Standard Management. 2020;11(23):41-3. doi:10.3969/j.issn.1674-9316.2020.23.014.
25 Wang H, Li X, Chen J. Impact of "4+7" City Drug Centralized Procurement Program on the utilization of original and generic cardiovascular drugs in a tertiary hospital. Journal of Pharmaceutical Practice. 2020;38(04):373-8. doi:10.12206/j.issn.1006-0111.202001054.
26 Yang Q, Guo W, Liu S. Effects of procuring with target quantity on using antipsychotics at a hospital. Chinese Journal of Hospital Pharmacy. 2020:1-6. doi:10.13286/j.1001-5213.2021.04.13.
27 Tang Y, Chen J, Li X. Utilization Analysis of the Original and Generic Drugs for Hypertension and Diabetes in a Tertiary Public Hospital in Jiangsu Province. China Pharmacy. 2019;30(21):2890-4. doi:10.6039/j.issn.1001-0408.2019.21.03.
28 Wang J, Yang Y, Xu L, Shen Y, Wen X, Mao L et al. The impact of National Centralized Drug Procurement policy on the use of policy-related original and generic drugs in public medical institutions in China: A difference-in-difference analysis based on national database. medRxiv 2021.06.21.21256568. 2021. doi:https://doi.org/10.1101/2021.06.21.21256568.
29 Wang Y, Wu Z. Keypoint Analysis of Monitoring Plan for Centralized Drug Purchase and Use Project Pilot Launched Organized by State. China Pharmacy. 2019;30(17):2317-22. doi:10.6039/j.issn.1001-0408.2019.17.03.
30 WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2021. 2021.https://www.whocc.no/atc_ddd_index/.
31 WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2021, Norway. 2021.http://www.whocc.no.
32 Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J CLIN PHARM THER. 2002;27(4):299-309. doi:10.1046/j.1365-2710.2002.00430.x.
33 Jandoc R, Burden AM, Mamdani M, Lévesque LE, Cadarette SM. Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. J CLIN EPIDEMIOL. 2015;68(8):950-6. doi:10.1016/j.jclinepi.2014.12.018.
34 Lagarde M. How to do (or not to do) ... Assessing the impact of a policy change with routine longitudinal data. HEALTH POLICY PLANN. 2011;27(1):76-83. doi:10.1093/heapol/czr004.
35 Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. J CLIN EPIDEMIOL. 2009;62(2):143-8. doi:10.1016/j.jclinepi.2008.08.007.
36 National Healthcare Security Administration of the People's Republic of China. Answer to Reporters' Request about the Second Round of National Centralized Drug Procurement and Use. 2020.http://www.nhsa.gov.cn/art/2020/1/17/art_38_2264.html.
37 Yu C. The practical effects and system concerns of "4+7" drug procurement. Journal of Southwest Minzu University (Humanities and Social Science). 2020;41(04):34-9
38 An Y, Tang J, Mao C, Ai C. Pharmacoeconomic evaluation on the influence of national centralized drug procurement on medical insurance patients. Clinical Medication Journal. 2020;18(11):10-3. doi:10.3969/j.issn.1672-3384.2020.11.003.
39 Hu S. The Health Economics Theoretical Basis and Improvement Suggestions for the National Centralized Drug Procurement. Chinese Health Resources. 2021:1-4. doi:10.13688/j.cnki.chr.2021.200942.
40 The Central People's Government of the People's Republic of China. China's centralized drug procurement is steadily advancing. 2020.http://www.gov.cn/xinwen/2020-10/14/content_5551115.htm.
41 Chen L, Yang Y, Luo M, Hu B, Yin S, Mao Z. The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China. Int J Environ Res Public Health. 2020;17(24). doi:10.3390/ijerph17249415.
42 Yang Y, Chen L, Ke X, Mao Z, Zheng B. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis. BMC HEALTH SERV RES. 2021;21(1):668. doi:10.1186/s12913-021-06698-5.
43 He J, Tang M, Cong L, Xu Y, Song J, Chen M et al. The impact of National Centralized Drug Procurement on the clinical management and drug use. Chinese Health Resources. 2021:1-3. doi:10.13688/j.cnki.chr.2021.200802.